|
1.
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar
|
|
2.
|
Lee AK: Radiation therapy combined with
hormone therapy for prostate cancer. Semin Radiat Oncol. 16:20–28.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Molina A and Belldegrun A: Novel
therapeutic strategies for castration resistant prostate cancer:
inhibition of persistent androgen production and androgen receptor
mediated signaling. J Urol. 185:787–794. 2011. View Article : Google Scholar
|
|
4.
|
Mlcochova J, Faltejskova P, Nemecek R,
Svoboda M and Slaby O: MicroRNAs targeting EGFR signalling pathway
in colorectal cancer. J Cancer Res Clin Oncol. 139:1615–1624. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Shuch B, Mikhail M, Satagopan J, et al:
Racial disparity of epidermal growth factor receptor expression in
prostate cancer. J Clin Oncol. 22:4725–4729. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Syed S: Combination chemotherapy for
hormone-refractory prostate carcinoma: progress and pitfalls.
Cancer. 98:2088–2090. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Traish AM and Morgentaler A: Epidermal
growth factor receptor expression escapes androgen regulation in
prostate cancer: a potential molecular switch for tumour growth. Br
J Cancer. 101:1949–1956. 2009. View Article : Google Scholar
|
|
8.
|
Antonarakis ES, Carducci MA and
Eisenberger MA: Novel targeted therapeutics for metastatic
castration-resistant prostate cancer. Cancer Lett. 291:1–13. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Guttman M, Amit I, Garber M, et al:
Chromatin signature reveals over a thousand highly conserved large
non-coding RNAs in mammals. Nature. 458:223–227. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Prensner JR and Chinnaiyan AM: The
emergence of lncRNAs in cancer biology. Cancer Discov. 1:391–407.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Gupta RA, Shah N, Wang KC, et al: Long
non-coding RNA HOTAIR reprograms chromatin state to promote cancer
metastasis. Nature. 464:1071–1076. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Reis EM, Nakaya HI, Louro R, et al:
Antisense intronic non-coding RNA levels correlate to the degree of
tumor differentiation in prostate cancer. Oncogene. 23:6684–6692.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Prensner JR, Iyer MK, Balbin OA, et al:
Transcriptome sequencing across a prostate cancer cohort identifies
PCAT-1, an unannotated lincRNA implicated in disease progression.
Nat Biotechnol. 29:742–749. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Ji P, Diederichs S, Wang W, et al:
MALAT-1, a novel noncoding RNA, and thymosin beta4 predict
metastasis and survival in early-stage non-small cell lung cancer.
Oncogene. 22:8031–8041. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Petrovics G, Zhang W, Makarem M, et al:
Elevated expression of PCGEM1, a prostate-specific gene with cell
growth-promoting function, is associated with high-risk prostate
cancer patients. Oncogene. 23:605–611. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Srikantan V, Zou Z, Petrovics G, et al:
PCGEM1, a prostate-specific gene, is overexpressed in prostate
cancer. Proc Natl Acad Sci USA. 97:12216–12221. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Chung S, Nakagawa H, Uemura M, et al:
Association of a novel long non-coding RNA in 8q24 with prostate
cancer susceptibility. Cancer Sci. 102:245–252. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Cui Z, Ren S, Lu J, et al: The prostate
cancer-up-regulated long noncoding RNA PlncRNA-1 modulates
apoptosis and proliferation through reciprocal regulation of
androgen receptor. Urol Oncol. 31:1117–1123. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Lin R, Maeda S, Liu C, Karin M and
Edgington TS: A large noncoding RNA is a marker for murine
hepatocellular carcinomas and a spectrum of human carcinomas.
Oncogene. 26:851–858. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
de Kok JB, Verhaegh GW, Roelofs RW, et al:
DD3(PCA3), a very sensitive and specific marker to detect prostate
tumors. Cancer Res. 62:2695–2698. 2002.
|
|
21.
|
Hessels D, Klein Gunnewiek JM, van Oort I,
et al: DD3(PCA3)-based molecular urine analysis for the diagnosis
of prostate cancer. Eur Urol. 44:8–16. 2003. View Article : Google Scholar
|
|
22.
|
Xie BX, Zhang H, Yu L, et al: The
radiation response of androgen-refractory prostate cancer cell line
C4-2 derived from androgen-sensitive cell line LNCaP. Asian J
Androl. 12:405–414. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Horoszewicz JS, Leong SS, Kawinski E, et
al: LNCaP model of human prostatic carcinoma. Cancer Res.
43:1809–1818. 1983.
|
|
24.
|
Thalmann GN, Anezinis PE, Chang SM, et al:
Androgen-independent cancer progression and bone metastasis in the
LNCaP model of human prostate cancer. Cancer Res. 54:2577–2581.
1994.PubMed/NCBI
|
|
25.
|
Chen L, Mooso BA, Jathal MK, et al: Dual
EGFR/HER2 inhibition sensitizes prostate cancer cells to androgen
withdrawal by suppressing ErbB3. Clin Cancer Res. 17:6218–6228.
2011. View Article : Google Scholar
|
|
26.
|
Gutschner T and Diederichs S: The
hallmarks of cancer: a long non-coding RNA point of view. RNA Biol.
9:703–719. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Wang KC and Chang HY: Molecular mechanisms
of long noncoding RNAs. Mol Cell. 43:904–914. 2011. View Article : Google Scholar
|
|
28.
|
Ponting CP, Oliver PL and Reik W:
Evolution and functions of long noncoding RNAs. Cell. 136:629–641.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Roberts LD, Murray AJ, Menassa D, Ashmore
T, Nicholls AW and Griffin JL: The contrasting roles of PPARdelta
and PPARgamma in regulating the metabolic switch between oxidation
and storage of fats in white adipose tissue. Genome Biol.
12:R752011. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Cheng W, Zhang Z and Wang J: Long
noncoding RNAs: New players in prostate cancer. Cancer Lett.
339:8–14. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Bussemakers MJ, van Bokhoven A, Verhaegh
GW, et al: DD3: a new prostate-specific gene, highly overexpressed
in prostate cancer. Cancer Res. 59:5975–5979. 1999.PubMed/NCBI
|
|
32.
|
Bu D, Yu K, Sun S, et al: NONCODE v3.0:
integrative annotation of long noncoding RNAs. Nucleic Acids Res.
40:D210–D215. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Takayama K, Horie-Inoue K, Katayama S, et
al: Androgen-responsive long noncoding RNA CTBP1-AS promotes
prostate cancer. EMBO J. 32:1665–1680. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Mimeault M and Batra SK: Recent advances
on multiple tumorigenic cascades involved in prostatic cancer
progression and targeting therapies. Carcinogenesis. 27:1–22. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Nickerson T, Chang F, Lorimer D, Smeekens
SP, Sawyers CL and Pollak M: In vivo progression of LAPC-9 and
LNCaP prostate cancer models to androgen independence is associated
with increased expression of insulin-like growth factor I (IGF-I)
and IGF-I receptor (IGF-IR). Cancer Res. 61:6276–6280.
2001.PubMed/NCBI
|
|
36.
|
Xie BX, Zhang H, Wang J, et al: Analysis
of differentially expressed genes in LNCaP prostate cancer
progression model. J Androl. 32:170–182. 2011. View Article : Google Scholar : PubMed/NCBI
|
